Results 121 to 130 of about 53,817 (192)

Re-use of erlotinib in a patient using osimertinib after erlotinib, case report

, 1995
Introduction Most patients with non-small-cell lung cancer tumors that have epidermal growth factor receptor (EGFR) mutations have deletion mutations in exon 19 or exon 21, or both.In recent years, targeted therapies in lung cancer have increased ...
Ünal, Vahdet, Gursoy, Pinar
core   +1 more source

Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer

, 2011
Purpose Sorafenib, an oral multikinase inhibitor, has shown preliminary activity in non–small-cell lung cancer (NSCLC). Patients with advanced NSCLC were treated with erlotinib with or without sorafenib in this multicenter phase II trial.
Elke K. Friedman, David R. Spigel, R. Brian Mitchell, J. David Bass, F. Anthony Greco, David M. Waterhouse, Jeffrey Zangmeister, Howard A. Burris, John D. Hainsworth, Davey B. Daniel, Robert C. Whorf, Dianna L. Shipley   +11 more
core   +1 more source

Targeting ferroptosis pathway to overcome erlotinib resistance

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. For advanced NSCLC, targeted therapies are often recommended to improve prognosis by acting on specific genetic mutations.
Hou, Tianxu
core   +1 more source

Erlotinib in the trentment of Advanced Non-small-cell Lung Cancer: A Systematic Review

Chinese Journal of Lung Cancer, 2009
Background and objective Erlotinib is a new and efficient anti-tumor targeted therapy drug, and it has been used in China for non-small cell lung cancer since 2006. The aim of this study is to review the effectiveness and safety of erlotinib for treating
Yanming TANG, Shiyong WANG, Zhenjun YANG, Lina ZHU   +3 more
doaj  

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer

, 2012
Alain Vergnenègre1, Joshua A Ray2, Christos Chouaid3, Francesco Grossi4, Helge G Bischoff5, David F Heigener6, Stefan Walzer21Department of Pneumology, Hôpital du Cluzeau, Limoges, France; 2Global Health Economics and Strategic ...
Chouaid C, Bischoff HG, Vergnenègre A, Grossi F, Heigener DF, Ray JA, Walzer S, Walzer S, Vergnenègre A   +8 more
core  

Persistent TOP1 cleavage complexes in drug-tolerant cells drive adaptive resistance to EGFR-targeted therapies in lung cancer. [PDF]

Sci Adv
Geraud M, Gence R, Casanova A, Taranchon-Clermont E, Salimbeni S, Özsu N, Vienne M, Delahaye C, Borrull E, Lusque A, Morisseau M, Filleron T, Pagan D, Taha C, Cristini A, Mazières J, Calvayrac O, Favre G, Pradines A, Sordet O.   +19 more
europepmc   +1 more source

A systematic review and network meta-analysis of first-line EGFR-TKI-based combination strategies for EGFR-mutant non-small cell lung cancer with brain metastases. [PDF]

Sci Rep
Ma J, Zhao W, Guo W, Li Z, Lu X, Yang X, Jia C, Zhou Q, Jiang J.   +8 more
europepmc   +1 more source

RAF1 extrachromosomal DNA amplification confers acquired erlotinib resistance in a non-small cell lung cancer cell model. [PDF]

Signal Transduct Target Ther
Kim S, Kim B, Lim A, Kim H, Cho J.
europepmc   +1 more source

Osimertinib <i>vs.</i> erlotinib combined with an angiogenesis inhibitor in <i>EGFR</i>-mutated non-small cell lung cancer with malignant pleural effusion: a retrospective cohort study. [PDF]

Transl Lung Cancer Res
Hata T, Yamada T, Mikami K, Yokoyama T, Oba T, Goto Y, Furuya N, Futamura S, Taniguchi H, Okimoto T, Hirai S, Uda S, Okada A, Watanabe R, Ishizaki N, Kawachi H, Kijima T, Takayama K.   +17 more
europepmc   +1 more source

Global pharmacovigilance analysis of dermatologic toxicity in EGFR-TKI-treated NSCLC: a cross-database real-world study. [PDF]

Front Pharmacol
Sauer N, Giedziun P, Calik J, Wiela-Hojeńska A.   +3 more
europepmc   +1 more source